Kohmann Bosshard Financial Services LLC Increases Holdings in Eli Lilly and Company (NYSE:LLY)

Kohmann Bosshard Financial Services LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 5.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 413 shares of the company’s stock after buying an additional 23 shares during the period. Kohmann Bosshard Financial Services LLC’s holdings in Eli Lilly and Company were worth $319,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. Values Added Financial LLC grew its position in Eli Lilly and Company by 4.9% during the 3rd quarter. Values Added Financial LLC now owns 366 shares of the company’s stock worth $324,000 after acquiring an additional 17 shares during the last quarter. Pursue Wealth Partners LLC bought a new position in Eli Lilly and Company during the 3rd quarter worth approximately $364,000. Creative Financial Designs Inc. ADV grew its position in Eli Lilly and Company by 2.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 16,339 shares of the company’s stock worth $14,475,000 after acquiring an additional 325 shares during the last quarter. Lebenthal Global Advisors LLC grew its position in Eli Lilly and Company by 12.6% during the 3rd quarter. Lebenthal Global Advisors LLC now owns 2,177 shares of the company’s stock worth $1,929,000 after acquiring an additional 243 shares during the last quarter. Finally, Interchange Capital Partners LLC grew its position in Eli Lilly and Company by 2.2% during the 3rd quarter. Interchange Capital Partners LLC now owns 1,061 shares of the company’s stock worth $940,000 after acquiring an additional 23 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Up 1.7 %

Shares of NYSE:LLY opened at $920.44 on Friday. The stock has a fifty day simple moving average of $814.88 and a two-hundred day simple moving average of $848.69. The stock has a market capitalization of $872.73 billion, a price-to-earnings ratio of 78.60, a PEG ratio of 1.40 and a beta of 0.42. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its board has authorized a stock buyback program on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.65%. Eli Lilly and Company’s payout ratio is presently 51.24%.

Analysts Set New Price Targets

Several research firms recently issued reports on LLY. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research report on Thursday, January 16th. Bank of America reiterated a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Truist Financial lifted their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Wolfe Research started coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective on the stock. Finally, Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,000.28.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.